Whalegun
Lobbying

Intra-Cellular Therapies's latest lobbying report covers Q4 2025, at $50K. The four quarters Q4 2025–Q3 2026 total $50K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.

Intra-Cellular Therapies

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$50K
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Intra-Cellular Therapies lobbying by quarter
Intra-Cellular Therapies lobbying by quarter
QuarterAmountReports
Q4 2022$80K2
Q1 2023$120K2
Q2 2023$50K2
Q3 2023$50K2
Q4 2023$80K2
Q1 2024$100K2
Q2 2024$100K2
Q3 2024$100K2
Q4 2024$90K2
Q1 2025$120K2
Q2 2025$20K2
Q3 2025$50K2
Q4 2025$50K1
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$625K · 21 reports
  • Medicare and Medicaid$250K · 11 reports
  • Taxation$135K · 8 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES23 reports
  • SENATE22 reports
  • Centers For Medicare and Medicaid Services (CMS)7 reports

Firms it paid

Firm
In-houseIntra-Cellular Therapies$510K12 quarters
Dla Piper$500K13 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
01/16for Q4 2025Dla Piper$50K
25/10/16for Q3 2025Dla Piper$50K
25/10/10for Q3 2025In-houseUnder $5,000
25/07/21for Q2 2025Dla Piper$10K
25/07/21for Q2 2025In-house$10K
25/04/21for Q1 2025Dla Piper$50K
25/04/21for Q1 2025In-house$70K
25/01/17for Q4 2024In-house$40K
25/01/17for Q4 2024Dla Piper$50K
24/10/21for Q3 2024Dla Piper$50K
24/10/21for Q3 2024In-house$50K
24/07/22for Q2 2024In-house$50K
24/07/22for Q2 2024Dla Piper$50K
24/04/22for Q1 2024Dla Piper$30K
24/04/22for Q1 2024In-house$70K
24/01/22for Q4 2023Dla Piper$40K
24/01/18for Q4 2023In-house$40K
23/10/20for Q3 2023Dla Piper$40K
23/10/19for Q3 2023In-house$10K
23/07/20for Q2 2023Dla Piper$10K